MapLight Therapeutics, Inc. (“MapLight”) (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an investigational novel M 1 ...
Vanderbilt University has synthesized muscarinic M4 receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia and sleep ...
Cerevel Therapeutics Inc. has identified compounds acting as muscarinic M4 receptor agonists reported be useful for the treatment of pain, sleep disorders, schizophrenia, substance abuse and ...
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback